Entries by

Rentschler Biopharma and XL-protein demonstrate efficient production of a hyperactive PASylated DNase I with extended half-life

26. October 2021 in /by

Hyperactive DNase I modified with XL-protein’s PASylation® technology demonstrated significantly extended systemic half-life in vivo, potentially offering improved treatment options for autoimmune diseases and cystic fibrosis. Potential for high-yield manufacturing of other PASylated protein therapeutics in mammalian cell culture on Rentschler Biopharma’s bioprocessing platform. Laupheim and Freising, Germany, October 26, 2021 – Rentschler Biopharma SE, a […]

XL-protein announces the Avi-PA(S)™ MAb platform to boost the preclinical and clinical development of therapies using its PASylation® technology

12. July 2021 in /by

FREISING, GERMANY, July 12, 2021 – XL-protein GmbH, a German biotech company specialised in the development of biopharmaceuticals with extended half-life, announced today that key scientific data have been published in the Journal of Molecular Biology (2021, Vol. 433, Pub. no. 167113). The Open Access Publication “Molecular recognition of structurally disordered Pro/Ala-rich sequences (PAS) by […]

Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis

25. February 2021 in /by

NEW YORK and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, announced today the publication of new data in the journal CELLS. The paper, entitled “Immune-Mediated Retinal Vasculitis […]

XL-protein and Antlia Bioscience Announce Collaboration to Develop Long-acting Peptide Therapy of Chronic Heart Failure using PASylation® Technology

15. October 2020 in /by

SAN DIEGO, U.S.A., and FREISING, Germany, 15th October, 2020: Antlia Bioscience, Inc., a privately owned biopharmaceutical company located in San Diego, California, and XL-protein GmbH, a privately owned biopharmaceutical company located in Germany, are pleased to announce a Strategic Alliance using XL-protein’s proprietary PASylation® technology for plasma half-life extension to develop a novel, long-acting, peptide therapeutic treatment for chronic heart failure. […]

XL-protein and DNX Biopharmaceuticals Announce Collaboration to Develop Novel Inflammasome-Directed Therapeutics using PASylation® Technology

25. February 2020 in /by

Freising, Germany and San Diego, CA, February 25, 2020 — XL-protein has extended its existing partnership with DNX Biopharmaceuticals, a biopharmaceutical company developing nonimmunogenic, long-acting therapeutic proteins for the treatment of patients with life-long diseases, to develop novel inflammasome-directed therapeutics for the treatment of diseases linked to inflammation, autoinflammation and oncology. DNX has exercised an […]

DNX Biopharmaceuticals Announces Collaboration With Lung Cancer Initiative at Johnson & Johnson

18. February 2020 in /by

San Diego, California–(Newsfile Corp. – February 18, 2020) – DNX Biopharmaceuticals, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases and a resident of Johnson & Johnson Innovation – JLABS, Shanghai, announced today that it has entered into a strategic collaboration with the Lung Cancer Initiative at Johnson & […]

Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases

27. January 2020 in /by

NEW YORK and LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces new preclinical data indicating that nomacopan significantly reduced both retinal inflammation and intraocular VEGF. Read more >

Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases

26. April 2019 in /by

NEW YORK and LONDON, April 26, 2019 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced encouraging new data in both the surface and the back of the eye. “This positive initial data […]

Ajinomoto and XL-protein forge Strategic Alliance to develop PASylated therapeutics applying the Corynex® platform

18. December 2018 in /by

SAN DIEGO, U.S.A., and FREISING, Germany, 18th December, 2018: Ajinomoto Bio-Pharma Services, a fully owned subsidiary of Ajinomoto Co. Inc. (TSE: 2802), and XL-protein GmbH, a privately owned German biopharmaceutical company, are pleased to announce a Strategic Alliance. Ajinomoto will apply its proprietary Corynex® expression system together with XL-protein’s proprietary PASylation® technology for plasma half-life […]

Horizon Pharma plc and XL-protein GmbH have entered into a collaboration agreement on a potential next-generation biologic for uncontrolled gout using PASylation® technology

7. January 2018 in /by

FREISING, January 9, 2018 /XL-protein/ — Horizon Pharma plc (NASDAQ:HZNP) yesterday announced that it has entered into a collaboration agreement with XL-protein GmbH to identify clinical-stage program candidates that could use PASylation® technology to construct a next-generation gout biologic. PASylation® technology is a biological alternative to synthetic PEGylation and is intended to extend both the […]